| Document |
Document Title |
|
WO/2023/224431A1 |
The present invention relates to a pharmaceutical composition comprising, as an active ingredient, hypothalamus-like organoid-derived neural stem cells for preventing and treating geriatric diseases. It was found that decreased memory, c...
|
|
WO/2023/224989A1 |
The present disclosure provides compounds, compositions, and/or methods for treating, preventing, inhibiting, ameliorating, or delaying the onset of Huntington's disease and/or a HTT proteinopathy in a subject. The methods can comprise a...
|
|
WO/2023/224372A1 |
The present invention relates to a Prevotella histicola strain useful for the prevention or treatment of sleep disorders. Prevotella histicola exhibits an increase in total sleep time, non-REM (NREM) sleep time and REM sleep time, and a ...
|
|
WO/2023/222705A1 |
Composition comprising a combination of fisetin or derivative thereof and quercetin or derivative thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional sup...
|
|
WO/2023/224604A1 |
The present invention primarily relates to the use of a fragrance composition for conveying a positive mood in a subject, preferably a human, as well as to the use of a product containing the fragrance composition. Furthermore, the prese...
|
|
WO/2023/225596A1 |
Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and...
|
|
WO/2023/223172A1 |
Provided are compositions comprising terpene mixtures consisting of 1000-4500 ppm myrcene, 1000-4000 ppm terpineol, 1000-5500 ppm caryophyllene and 1000-45000 ppm nerolidol; 1000-4500 ppm alpha-pinene, 1000-4000 ppm sabinene, 1000-4000 p...
|
|
WO/2023/225511A1 |
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2...
|
|
WO/2023/224833A1 |
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include recombinant protein constructs employing human TIMP-2 protein for use in treating indications re...
|
|
WO/2023/222871A1 |
The present invention relates to proteins and polypeptides from the salivary gland of Ixodes ricinus for their use for preventing and/or treating brain inflammation and diseases or conditions associated with brain inflammation, and metho...
|
|
WO/2023/225125A1 |
A method of monitoring and treating a subject with ALS based on biomarkers. In some embodiments, the method comprises: identifying that a subject has a ratio of LPS1EGF associated with ALS; and based on the identifying that the subject h...
|
|
WO/2023/222924A1 |
The present invention concerns Lachnospiraceae spp and Ruminococcus lactaris new strains of bacteria for use solely or in combination, in the treatment and prevention of memory decline in an individual, in particular declines of aging or...
|
|
WO/2023/225640A2 |
Epilepsy is one of the most common neurological disorders. However, there are currently no drugs available to prevent and/or reduce the development of said disorder. Thus, compositions and methods described herein prevent and/or arrest t...
|
|
WO/2023/222124A1 |
Disclosed in the present invention are a 5,6-dihydro-1,2,4-triazine compound and the pharmaceutical use thereof as a GLP-1 receptor agonist. A structure of the 5,6-dihydro-1,2,4-triazine compound is represented by formula (I), and in the...
|
|
WO/2023/221814A1 |
Disclosed is a long-acting sustained-release preparation pharmaceutical composition containing pramipexole, comprising a pharmaceutically acceptable salt of pramipexole and a pharmaceutical high polymer material. The preparation is selec...
|
|
WO/2023/225190A1 |
Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering from the disease at least one Retinoid X receptor gamma (RXRy) agonist and at least o...
|
|
WO/2023/222080A1 |
A pharmaceutical composition is provided. The pharmaceutical composition comprises an active pharmaceutical ingredient (API), a polymer and a solvent. The API comprsises cariprazine, a pharmaceutically acceptable salt of cariprazine, or ...
|
|
WO/2023/225244A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
|
|
WO/2023/222005A1 |
The present invention belongs to the technical field of medicines, and relates to a class of aromatic heterocyclic compounds serving as an LRRK2 inhibitor. The present invention provides a class of compounds with a novel structure, which...
|
|
WO/2023/225249A1 |
Described herein are methods relating to the treatment of certain diseases with an agonist of Mfsd2A, and the treatment of certain other diseases with an inhibitor of Mfsd2A.
|
|
WO/2023/221892A1 |
The present invention relates to antibodies specifically binding to α-Synuclein or antigen-binding fragments thereof, a pharmaceutical composition containing the antibodies or the antigen-binding fragments thereof, a nucleic acid molecu...
|
|
WO/2023/225507A1 |
The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.
|
|
WO/2023/224178A1 |
The present invention relates to a pharmaceutical composition and functional health food for preventing, treating, or ameliorating angiogenetic diseases, more specifically to a pharmaceutical composition comprising SHC1 protein or anti-S...
|
|
WO/2023/224371A1 |
The present invention relates to a composition for preventing or treating neuroinflammatory diseases comprising a novel oxadiazole derivative compound or a pharmaceutically acceptable salt thereof. The present invention has excellent act...
|
|
WO/2023/225506A1 |
The invention relates to synthetic RNA molecules, nucleic acid constructs comprising the same. The invention further relates to methods of using the synthetic RNA molecules such as to deliver the synthetic RNA molecule to a cell, to trea...
|
|
WO/2023/222858A1 |
The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple inde...
|
|
WO/2023/225206A1 |
Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering the disease a combination of at least one muscarinic receptor antagonist and at least...
|
|
WO/2023/220365A1 |
Described in certain example embodiments herein are methods of and compositions for treating a CASK-linked neurodevelopmental disorder. In certain example embodiments, the method includes administering, to a subject in need thereof, an a...
|
|
WO/2023/218868A1 |
This sympathetic nerve activator contains a compound represented by structural formula (1).
|
|
WO/2023/219511A1 |
The invention relates to combination or composition comprising: (i) nicotinic acid or a derivative thereof, and (ii) a fatty acid or a derivative thereof selected from tetradecylthioacetic acid 5 (TTA) or a derivative thereof. The invent...
|
|
WO/2023/220439A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
|
WO/2023/220433A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
|
WO/2023/220367A1 |
The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by intramuscular injection. Uses, formulations and kits...
|
|
WO/2023/218195A1 |
The invention provides compounds of formula (I) Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds...
|
|
WO/2023/219227A1 |
The administration of a composition of the present invention can suppress the accumulation of amyloid beta, leading to effective prevention, alleviation, or treatment of amyloidopathies, such as Alzheimer's disease.
|
|
WO/2023/220058A1 |
Disclosed are therapeutic methods for reducing the rate of functionality loss in patients suffering from amyotrophic lateral sclerosis (ALS) during the accelerated stages of this disease.
|
|
WO/2023/219939A1 |
The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role.
|
|
WO/2023/220084A1 |
Described herein, in part, are methods useful for preventing and/or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major de...
|
|
WO/2023/218023A1 |
The present invention relates to compounds of the formula (I) Formula (I) wherein Ar1, R1, R2, R3, X1, X2, Y, and Z are as described in the description, to their preparation, to pharmaceutically 5 acceptable salts thereof, and to their u...
|
|
WO/2023/217020A1 |
Disclosed in the present invention are an immunoglobulin κ-type light chain (Vκ4-1-IgLC) polypeptide having a unique Vκ4-1 and the use thereof. The amino acid sequence of the Vκ4-1-IgLC polypeptide is as shown in SEQ ID NO.1, and the...
|
|
WO/2023/219468A1 |
The present invention relates to a composition comprising dopamine-hyaluronic acid for treating Parkinson's disease and, particularly, to a therapeutic composition for supplying dopamine to nerve cells as a dopamine mimic. The compositio...
|
|
WO/2023/218364A1 |
The present invention provides an anti-aging and anti-inflammatory composition comprising nicotinamide mononucleotide (NMN) or an analog thereof, and certain antioxidants, more specifically resveratrol and at least of ergothioneine and h...
|
|
WO/2023/220366A1 |
The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by subcutaneous injection. Uses, formulations and kits ...
|
|
WO/2023/215984A1 |
The present application includes a composition comprising a non-racemic mixture R-1,3-butanediol and S-1,3-butanediol, wherein the R-1,3-butanediol is present in the composition in a greater amount by enantiomeric equivalents, relative t...
|
|
WO/2023/218187A1 |
Disclosed are heterobifunctional compounds that can induce the degradation of leucine-rich repeat kinase 2 (LRRK2) and PDE6D. These compounds can engage LRRK2 on one end and bind to an ubiquitin E3 ligase (e.g. cereblon, Von Hippel-Linda...
|
|
WO/2023/219164A1 |
This pharmaceutical is used in a method including a step A for administering a bubble to a mammal and irradiating a target region in the mammal with ultrasound, and a step B for administering a composite to the mammal. The pharmaceutical...
|
|
WO/2023/219140A1 |
An inhibitory neuron-specific promoter sequence is discovered, which has a shorter length compared with a mGAD65 promoter and is not deteriorated in all of a promoter activity, specificity to an inhibitory neuron and a gene expression ef...
|
|
WO/2023/220370A1 |
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase ("BTK") inhibitors, for treatment of subjects with myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
|
|
WO/2023/218453A1 |
Provided are methods of treating a subject having a disease associated with a polyalanine expansion mutation, by administering to the subject a therapeutically effective amount of an agent capable of upregulating expression or activity o...
|
|
WO/2023/220287A1 |
Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Specifically, the targeting peptide is a component of a modified, se...
|
